Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zebitumumab-based regimen in hormone-ineffective immune thrombocytopenia
ChiCTR2400090793Phase 4Not yet recruiting
- Sponsor
- Pingdingshan First People's Hospital
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of zebitumumab in immune thrombocytopenia (ITP) (2 arms), sponsored by Pingdingshan First People's Hospital. Primary endpoint: platelet count. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
zebitumumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2400090793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090793.